Recent Updates
Recently added Catalysts

Comparator: HPV 16 L1 Vaccine

Phase 2

HPV 16 Infection | Monoclonal antibody | Infectious Disease |Merck & Company, Inc.|Last Updated: Oct 23, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment2,409
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00365378Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)PHASE2 COMPLETED 2,409Sep 1, 1999Jul 1, 2009Oct 23, 2015 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence of Persistent HPV 16 Infection
Through Month 48

Cases of persistent infection were those with detection of HPV 16 by PCR (Polymerase chain reaction) on at least 2 consecutive visits at least 4 months apart; or detection of HPV 16 in a cervical biopsy specimen showing pathologic evidence of CIN1 (Cervical intraepithelial neoplasia), CIN2 or CIN3 together with HPV 16 detected at the visit immediately before or after the biopsy; or detection of HPV 16 on a subject's last visit.

Incidence of HPV 16-related CIN1, CIN2 or C1N3
Through Month 48

Cases of HPV 16-related CIN1, CIN2 or CIN3 are those with detection of HPV 16 in a cervical biopsy specimen showing pathologic evidence of CIN1, CIN2 or CIN3 together with HPV 16 detected at the visit immediately before or after the biopsy.

Serum Anti-HPV 16 Geometric Mean Titers
Month 7

The limit of detection of the assay was 6 mMU/ml. Samples with titer below the limit of detection were assigned a value of 3 for calculation of GMT and confidence interval. GMTs and confidence limits below the limit of detection are shown as "6.0".

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
1EXPERIMENTALHPV 16 L1 VLP vaccine
2PLACEBO_COMPARATORPlacebo
Interventions
NameTypeDescription
Comparator: HPV 16 L1 VaccineBIOLOGICALA 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
Comparator: PlaceboBIOLOGICALA 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
Unlock Study Design Details
Eligibility Criteria
Age Range16 Years — 23 Years
SexFEMALE
Healthy VolunteersYes

Inclusion Criteria: * Healthy, unmarried females age 16 to 23 years with intact uteri * Not pregnant at enrollment * Agreed to use effective contraception through Month 7 of the study * A lifetime history of 0 to 5 male partners with whom the subjects engaged in at least one episode of insertive in...

Unlock Eligibility Criteria